Three new drugs of Fangsheng pharmaceutical have been approved for clinical trials
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Three new drug varieties of Fangsheng pharmaceutical were approved for clinical trials, namely terbinafine hydrochloride tablets, losartan potassium tablets and lamivudine tablets Terbinafine hydrochloride is an anti fungal drug Losartan potassium is a selective and competitive antagonist for the treatment of hypertension Lamivudine is a drug for the treatment of hepatitis B The three new drug varieties are all class B of national medical insurance The clinical trial cycle is long, the short-term has no contribution to the performance, but it is conducive to the long-term development.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
